Indeed, in ICI-resistant murine models, the combination of anti-CTLA-4 or anti-PD-1 mAbs with IPI-549 significantly delayed tumor growth in comparison to ICI monotherapies (De Henau et al., 2016). Here, CTLA4 is linked to neoplasm.